WAMIF: Prospective Study in Young Women Presenting Acute Myocardial Infarction: Cohort Follow up

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-60
SponsorFrench Cardiology Society

About this trial

The WAMIF study was conducted from 2017 to 2019, including 314 patients in 30 French research centers spread across metropolitan France. It systematically collected the clinical, morphological, and biological characteristics of myocardial infarction cases affecting women under 50 years of age and assessed their short-term (in-hospital) and medium-term (12-month) prognosis. Extending the follow-up beyond 12 months for this first study would provide fundamental data for understanding and improving the care of these patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

314 women who had a myocardial infarction at less than 50 years, included in the WAMIF study conducted from 2017 to 2019 in 30 French research centers.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Questionnaires

    Other intervention

    Assessment of stress and anxiety and quality of life after myocardial infarct: * Stress score: Perceived Stress Scale-4 (PSS-4) * Anxiety score: Generalized Anxiety Disorder-7 (GAD-7) * Depression score: Patient Health Questionnaire-9 (PHQ-9) * Quality of life scores: European Quality of Life-5 Dimensions (EQ-5D) and 12-Item Short-Form General Health Survey (SF-12)

  • Major events

    Other intervention

    Collection of information related to major events occurring since inclusion in the WAMIF study

Treatment groups

314 Participants
are divided into 1 treatment group
Group A: WAMIF patients2 interventions

Trial outcomes

Primary outcomes

1

Death from any cause

Number of patient who died from any cause since their participation in WAMIF study

Time frame
5 to 10 years after the participation in WAMIF study
2

Cardiovascular death

Number of patient who died from cardiovascular cause since their participation in WAMIF study

Time frame
5 to 10 years after the participation in WAMIF study
3

Stent thrombosis

Number of patient who had stent thrombosis since their participation in WAMIF study

Time frame
5 to 10 years after the participation in WAMIF study
4

Stroke

Number of patient who had stroke since their participation in WAMIF study

Time frame
5 to 10 years after the participation in WAMIF study

Secondary outcomes

1

Stress score

Perceived Stress Scale 4 items. It provides a total score (range 10-50, from worst to best) to assess the state of stress perceived by the patient

Time frame
5 to 10 years after the participation in WAMIF study
2

Anxiety score

Generalized Anxiety Disorder 7 items. It provides a total score to evaluate patient anxiety (range 0 to 21: 0-4: minimal anxiety; 5-9: mild anxiety; 10-14: moderate anxiety; 15-21: severe anxiety)

Time frame
5 to 10 years after the participation in WAMIF study
3

Depression score

Patient Health Questionnaire 9 items. It provides a total score (range 0-27, 1-4 minimal depression; 5-9 mild depression; 10-14 moderate depression; 15-19 moderately severe depression; 20-27 severe depression) to diagnose and measure severity of depression.

Time frame
5 to 10 years after the participation in WAMIF study
4

Quality of life score

European Quality of Life 5 Dimensions. It provides a total score (range 0-100, from worst to the best) to evaluate the generic quality of life

Time frame
5 to 10 years after the participation in WAMIF study

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.